Safety Profile

Learn about the possible side effects of Doptelet® (avatrombopag).

Doptelet Platelet Characters in the Woods at Sunset

Doptelet has an established safety profile1,2

Adverse reactions with a frequency ≥10% in adults with chronic ITP treated with Doptelet—
pooled data from clinical trials.1*

Adverse ReactionDoptelet
Upper Respiratory Tract Infection155
Gingival Bleeding130

Doptelet has no reported interactions with statins, no cataracts precautions, and no associated liver damage.1,3†

*The American Society of Hematology (ASH) guidelines define a durable response as platelet count ≥30x109/L and at least doubling of the baseline count at 6 months.4

Doptelet had no significant liver damage reported in clinical trials. Therefore, no additional liver function monitoring is required.2

Doptelet Safety and Tolerability

Thrombotic/Thromboembolic Complications1

  • In clinical trials in patients with chronic ITP, 7% (9/128) of patients treated with Doptelet developed a thromboembolic event

Serious Adverse Reactions1,2

  • Serious adverse reactions that occurred more frequently in patients with chronic ITP treated with Doptelet (9%; 12/128) compared to placebo (5%; 1/22) included headache, occurring in 1.6% (2/128)

  • Adverse reactions resulting in discontinuation of Doptelet that were reported in more than 1 patient included headache, occurring in 1.6% (2/128)

Doptelet Platelet Characters Having a Picnic

Discover Doptelet dosing

Learn how to titrate Doptelet with our titration calculator.


  1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
  2. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490. 
  3. DOPTELET (avatrombopag) [patient information leaflet]. Durham, NC: AkaRx, Inc; 2021.
  4. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.